Pliant Therapeutics, Inc. entered into a loan agreement for up to $150 million and announced the implementation of a Phase 2b/3 trial for bexotegrast in patients with idiopathic pulmonary fibrosis.
AI Assistant
PLIANT THERAPEUTICS INC
2024
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.